- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 26, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from mHealthIntelligence referenced a study published in the January 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Characterizing Telehealth Use in the US: Analysis of the 2022 Health Information National Trends Survey,” concluded that discussing the motivation of patients to use telehealth could help policy makers and administrators to maximize health care access and quality.
An article from Good Men Project referenced an article published in the April 2021 issue of AJMC. The piece, “Enhance Care Continuity Post COVID-19,” argued that the pandemic had created an opportunity to augment continuity to improve patient-centered outcomes and improve spending efficiency.
An article from Biospace referenced an article published on AJMC.com, the website of AJMC. The article, “Analysis Explores Gene Therapy’s Potential to Be Cost-Effective in SCD,” reported gene therapy in the treatment of sickle cell disease could be cost effective if it was priced below the $2 million mark.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More
